Quizartinib Sparks Remission in Some Patients With Resistant AMLDecember 18th 2012
Quizartinib, a novel tyrosine kinase inhibitor, demonstrated a clinical benefit in patients with a particularly deadly form of acute myeloid leukemia in results of a phase II study presented during the 54th Annual ASH Meeting.
Ibrutinib Performance in CLL Patients HailedDecember 13th 2012
The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab, raising the prospect of a promising new therapy for elderly and frail patients who currently have few viable options.
Pomalidomide Labeled an Advance in Multiple MyelomaDecember 9th 2012
The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
Ponatinib Stimulates â€˜Powerfulâ€™ Response in Treatment-Resistant LeukemiasDecember 8th 2012
Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistanceâ€”including the stubborn T315I mutationâ€”in all stages of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).